DOSAGE FORM WITH SUSTAINED RELEASE MELATONIN PELLETS
A composition comprises a therapeutically effective oral pharmaceutical dosage form. The dosage form includes an aqueous carrier material having an acidic pH and a plurality of individual pellets having a first dose of melatonin therein. The individual pellets comprises (i) a solid core; (ii) an active coating over the solid core, the active coating including melatonin and a hydrophilic binder; and (iii) an enteric coating over the active coating. A dissolution pH of the enteric coating is higher than the acidic pH of the aqueous carrier material..
Medienart: |
Patent |
---|
Erscheinungsjahr: |
2022 |
---|---|
Erschienen: |
2022 |
Enthalten in: |
Europäisches Patentamt - (2022) vom: 23. Nov. Zur Gesamtaufnahme - year:2022 |
---|
Sprache: |
Englisch |
---|
Beteiligte Personen: |
SHAH SYED M [VerfasserIn] |
---|
Links: |
Volltext [kostenfrei] |
---|
Themen: |
Sonstige Themen: |
---|
Anmerkungen: |
Source: www.epo.org (no modifications made), First posted: 2022-11-23, Last update posted on www.tib.eu: 2023-06-04, Last updated: 2023-06-14 |
---|
Patentnummer: |
EP4090315 |
---|
Förderinstitution / Projekttitel: |
|
---|
PPN (Katalog-ID): |
EPA016554027 |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | EPA016554027 | ||
003 | DE-627 | ||
005 | 20230614162218.0 | ||
007 | cr uuu---uuuuu | ||
008 | 230607s2022 xx |||||o 00| ||eng c | ||
035 | |a (DE-627)EPA016554027 | ||
035 | |a (EPA)EP4090315 | ||
035 | |a (EPA)74285447 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 0 | |a SHAH SYED M |e verfasserin |4 aut | |
245 | 1 | 0 | |a DOSAGE FORM WITH SUSTAINED RELEASE MELATONIN PELLETS |
264 | 1 | |c 2022 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a Computermedien |b c |2 rdamedia | ||
338 | |a Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Source: www.epo.org (no modifications made), First posted: 2022-11-23, Last update posted on www.tib.eu: 2023-06-04, Last updated: 2023-06-14 | ||
520 | |a A composition comprises a therapeutically effective oral pharmaceutical dosage form. The dosage form includes an aqueous carrier material having an acidic pH and a plurality of individual pellets having a first dose of melatonin therein. The individual pellets comprises (i) a solid core; (ii) an active coating over the solid core, the active coating including melatonin and a hydrophilic binder; and (iii) an enteric coating over the active coating. A dissolution pH of the enteric coating is higher than the acidic pH of the aqueous carrier material. | ||
650 | 4 | |a che | |
650 | 4 | |a A61K: Preparations for medical, dental, or toilet purposes (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms a61j0003000000;chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles a61l; soap compositions c11d) | |
650 | 4 | |a 615 | |
700 | 0 | |a HASSAN DANIEL |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Europäisches Patentamt |g (2022) vom: 23. Nov. |
773 | 1 | 8 | |g year:2022 |g day:23 |g month:11 |
856 | 4 | 0 | |u https://worldwide.espacenet.com/patent/search/family/74285447/publication/EP4090315A1?q=EP4090315 |z kostenfrei |3 Volltext |
912 | |a GBV_EPA | ||
936 | u | w | |j 2022 |b 23 |c 11 |
951 | |a AR | ||
952 | |j 2022 |b 23 |c 11 |